September Buy Recommendations from Discerning Analysts

Twenty analysts have identified rare stock picks for September 2025, with healthcare stocks leading the list. Capricor Therapeutics (CAPR) is highlighted for its potential in treating DMD cardiomyopathy, while Barings BDC (BBDC) is recommended for its attractive valuation and high cash yield. Oscar Health (OSCR) is also mentioned for its expected rebound in 2026 driven by premium rate increases and improved pricing discipline. Gogo Inc. (GOGO) may be on the verge of a business turnaround, and FibroGen (FGEN) is highlighted for its potential in treating anemia.

Twenty analysts have identified rare stock picks for September 2025, with healthcare stocks leading the list. Among the highlighted opportunities are Capricor Therapeutics (CAPR), Barings BDC (BBDC), Oscar Health (OSCR), Gogo Inc. (GOGO), and FibroGen (FGEN). These stocks are recommended for their unique potential and strategic positioning in their respective sectors.

Capricor Therapeutics (CAPR) stands out for its potential in treating DMD cardiomyopathy, a rare and life-threatening condition. The company's lead drug candidate, deramiocel, is in the pipeline for a BLA resubmission and HOPE-3 topline data expected by 2026. With premium pricing potential and orphan market exclusivity, CAPR is positioned for significant upside if key milestones are achieved Capricor: Post-CRL Path To DMD Cardiomyopathy Approval In 2026^[2].

Barings BDC (BBDC) is recommended for its attractive valuation and high cash yield. The company trades at a 15% discount and pays a cash yield of 11% fully covered by net investment income. Its loans are mostly first lien, senior secured, and originated by the same Barings/MassMutual credit platform that has generated successful portfolios Capricor: Post-CRL Path To DMD Cardiomyopathy Approval In 2026^[2].

Oscar Health (OSCR) is expected to rebound in 2026 driven by significant premium rate increases and improved pricing discipline. The company's low valuation, strong revenue growth, and founder-led governance offer an attractive risk/reward profile Capricor: Post-CRL Path To DMD Cardiomyopathy Approval In 2026^[2].

Gogo Inc. (GOGO) may be on the verge of a business turnaround. With new management and regular target meetings, the company's Galileo and 5G services are expected to have a significant market impact. If these predictions hold true, GOGO could trade at a very attractive valuation Capricor: Post-CRL Path To DMD Cardiomyopathy Approval In 2026^[2].

FibroGen (FGEN) is highlighted for its potential in treating anemia. The company's lead drug candidate, roxadustat, is in clinical trials for the treatment of anemia in patients with chronic kidney disease. If successful, this could significantly expand FGEN's market reach Rare Stock Picks In September 2025 - From 20 Discerning Analysts^[3].

These rare stock picks reflect a mix of growth potential, strategic positioning, and attractive valuations. Investors should conduct thorough research and consider their risk tolerance before making any investment decisions.